R&D | February 04, 2026
Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
The new service delivers end-to-end support, managing every stage of an epigenomics project
The new service delivers end-to-end support, managing every stage of an epigenomics project
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The new functionality complements Parse’s existing Evercode immune products
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The partnership initially will focus on cardiovascular and kidney diseases
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Subscribe To Our Newsletter & Stay Updated
